These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 25060056)

  • 21. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.
    Fishbane S; Block GA; Loram L; Neylan J; Pergola PE; Uhlig K; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1851-1858. PubMed ID: 28082519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
    Fishbane SN; Singh AK; Cournoyer SH; Jindal KK; Fanti P; Guss CD; Lin VH; Pratt RD; Gupta A
    Nephrol Dial Transplant; 2015 Dec; 30(12):2019-26. PubMed ID: 26175145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
    Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
    Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.
    Jalal D; McFadden M; Dwyer JP; Umanath K; Aguilar E; Yagil Y; Greco B; Sika M; Lewis JB; Greene T; Goral S
    Hemodial Int; 2017 Apr; 21(2):243-249. PubMed ID: 27615161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
    Lee CT; Lee CC; Wu MJ; Chiu YW; Leu JG; Wu MS; Peng YS; Wu MS; Tarng DC
    PLoS One; 2022; 17(3):e0264727. PubMed ID: 35239732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
    Yokoyama K; Hashimoto T; Okuda Y; Matsumoto Y; Ito K; Yamada R; Susai H; Nishino N
    Clin Exp Nephrol; 2022 Jul; 26(7):688-699. PubMed ID: 35258721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
    Kapoian T; O'Mara NB; Singh AK; Moran J; Rizkala AR; Geronemus R; Kopelman RC; Dahl NV; Coyne DW
    J Am Soc Nephrol; 2008 Feb; 19(2):372-9. PubMed ID: 18216316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
    Yokoyama K; Hirakata H; Akiba T; Sawada K; Kumagai Y
    Am J Nephrol; 2012; 36(5):478-87. PubMed ID: 23147696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
    Shah HH; Hazzan AD; Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
    Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series.
    Tanemoto M; Ishimoto Y; Saito H
    Blood Purif; 2017; 43(1-3):97-100. PubMed ID: 27951582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: A meta-analysis in patients with chronic kidney disease.
    Choi YJ; Noh Y; Shin S
    Br J Clin Pharmacol; 2021 Feb; 87(2):414-426. PubMed ID: 32470149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.
    Wang Y; Chen X; Zhu H; Guo Z; Yang Y; Luo P; He Y; Xu Y; Ji D; Gao X; Sun X; Xing C; Wang Y; Wang X; Zhao S; Guan Y; Lin H; Zhong A; Shui H; Shao F; Lv L; Yan Y; Sun X; Zhang L
    Am J Nephrol; 2023; 54(11-12):479-488. PubMed ID: 37812931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
    McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
    Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.